Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …

Dysregulated cell division, which leads to aberrant cell proliferation, is one of the key
hallmarks of cancer. Therefore, therapeutic targets that block cell division would be effective …

Aberrancy in cell cycle progression is one of the fundamental mechanisms underlying
tumorigenesis, making regulators of the cell cycle machinery rational anticancer therapeutic …

Immunosurveillance is a critical mechanism guarding against tumor development and
progression. Checkpoint inhibitors have shown significant success in cancer treatment, but …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

Objective The diversity of the tumour microenvironment (TME) of intrahepatic
cholangiocarcinoma (iCCA) has not been comprehensively assessed. We aimed to …

Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune
checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could …

Cancer heterogeneity impacts therapeutic response, driving efforts to discover over-arching
rules that supersede variability. Here, we define pan-cancer binary classes based on distinct …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

Genomic and chromosomal instability are hallmarks of cancer and shape the genomic
composition of cancer cells, thereby determining their behavior and response to treatment …